Sales of biosimilar Remsima by South Korean bio-pharmaceutical firm Celltrion reached $77 million in the United States during the third quarter of this year, industry data showed Oct. 30.

Sales of the biosimilar drug to treat autoimmune diseases jumped 8 percent on-year during the July-September period, according to the earnings report by Pfizer.

Celltrion did not release data on sales of Remsima in the US as Pfizer is responsible for sales of the biosimilar drug under the name Inflectra.

Remsima is an identical copy of Janssen Biotech’s Remicade and is effective in treating various diseases, from rheumatoid arthritis to Crohn’s disease.

In contrast, sales of Remicade fell 24.1 percent on-year during the cited period.

By Ram Garikipati and newswires (ram@heraldcorp.com)